Moreover, a similar pattern (AR increased, CCL2 significantly decreased) is observed in metastases from patients who did not receive ADT (Supplementary Figure S6, Supplementary Table S1), supporting the idea that CCL2 is only required at the primary tumor site. This evidence concerns the gene CCL2 and neoplasm.